Design and Development of Ciclopirox Topical Nanoemulsion Gel for the Treatment of Subungual Onychomycosis

Onychomycosis is the most common infection of nails caused majorly by Trichophyton rubrum and Trichophyton mentagrophytes and minorly by yeasts. Topical delivery of available ciclopirox formulations as nail lacquer, cream, lotion, gel is hindered by the low permeability of human nail plates, and so there is need of repeated dosing for a longer period of time for effective treatment. In the present research work an attempt is made for effective delivery of ciclopirox olamine (CIC) across human nail plates by enahancing the penetration of CIC and retention time in skin layers. For this purpose nanoemulsion gel, composed of oil, surfactant, cosurfactant, and cabopol was developed by aqueous phase titration method and was evaluated for various in-vitro attributes. Oleic acid, tween 80, and PEG 400 were selected as oil, surfactant and co-surfactant respectively. Pseudoternary phase diagrams were plotted to get the range of nanoemulsion area. For the optimization of the formulation Box Benkhem model (RSM) was applied by taking size and zeta potential as dependant variables and formulation components were taken as independent variables. Total 17 formulations were suggested by the model, which were formulated and subjected to thermodynamic 2 stability study and permeation study. Among thermodynamically stable formulation, SF4 had shown lowest permeation across skin (56.672 µg/cm /h). SF4 formulation was further evaluated for skin retention study by fluorescent microscopy. Fluorescence microscopy studies were done over a period of 6 hrs clearly giving an indication of longer retention capability of the nano-gel formulation, for the desired topical action.

[1]  A. Munavvar,et al.  Formulation and in vitro evaluation of ketoprofen in palm oil esters nanoemulsion for topical delivery. , 2010, Journal of oleo science.

[2]  L. Cornelius,et al.  Current management of onychomycosis. , 2008, The Journal of hand surgery.

[3]  R. Hay,et al.  Review of antifungal therapy and the severity index for assessing onychomycosis: Part I , 2008, The Journal of dermatological treatment.

[4]  J. Parikh,et al.  Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level box-behnken design , 2007, AAPS PharmSciTech.

[5]  S. Murdan 1st Meeting on Topical Drug Delivery to the Nail , 2007, Expert opinion on drug delivery.

[6]  Sushma Talegaonkar,et al.  Development and bioavailability assessment of ramipril nanoemulsion formulation. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  D. Krajišnik,et al.  Characterization of caprylocaproyl macrogolglycerides based microemulsion drug delivery vehicles for an amphiphilic drug. , 2004, International journal of pharmaceutics.

[8]  M. Schaller,et al.  Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors , 2003, Antimicrobial Agents and Chemotherapy.

[9]  J. Robbins Treatment of onychomycosis in the diabetic patient population. , 2003, Journal of diabetes and its complications.

[10]  Paula Heinänen,et al.  In vitro evaluation of microcrystalline chitosan (MCCh) as gel-forming excipient in matrix granules. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  N. Zaias Clinical manifestations of onychomycosis , 1992, Clinical and experimental dermatology.